TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total Cholesterol Concentration of Chylomicron Fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of patients requiring opioids
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall Subjective and Objective Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With Undetectable HCV PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Elevation in Liver Enzyme >5 Times the Upper Limits
Endpoint domain: Adverse events/effects
Primary endpoint: Development of Acute Cholestatic Hepatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Intolerance to Direct Acting Antiviral Therapies
Endpoint domain: Adverse events/effects
Primary endpoint: diaphragm ultrasound motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Post-traumatic Stress Disorder (PTSD)
Endpoint domain: Adverse events/effects
Primary endpoint: Measure of quality of life (QoL) in MDS patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Measure of patient-reported outcomes (PRO) in MDS patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change From Baseline in Villous Height to Crypt Depth Ratio (VH:CD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: myeloperoxidase levels in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Saliva Secreted Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital course and outcome of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients requiring a surgical procedure for increased IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of patients requiring 1, 2, or 3 medications to control IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with IOP > 25mmHg on two occasions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients losing > 15 letters
Endpoint domain: Life impact
Endpoint subdomain: Visual functioning
Primary endpoint: Agreement in identification of abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (complete or partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Ketones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Seroconversion or Significant Increase to Influenza Vaccine Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients with mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of BP Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 Physical Functioning Subscore
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical Global Impression Scale (CGIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Geometric Mean Concentration of Serotype-specific Immunoglobulin G - Schedule A: 7-11 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Solicited Injection-site Adverse Events - Schedule A: 7-11 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least 1 Vaccine-related Serious Adverse Event - Schedule A: 7-11 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Point prevalent abstinence from all tobacco after 3 months
Endpoint domain: Physiological/clinical
Primary endpoint: Prolonged abstinence from all tobacco after 3 months
Endpoint domain: Physiological/clinical
Primary endpoint: Number of subjects who abstained for at least 24 hours
Endpoint domain: Physiological/clinical
Primary endpoint: Number of patients with malignant masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Change in Urine Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of subjects free of target limb failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormalities in laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity frequency and duration (Step count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Burden Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical and Radiographic Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HF self care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical therapeutic success (full regression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of PLP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with EGFR mutation detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative bleeding volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thromboembolism occurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chest tube drainage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dominant frequency of atrial fibrillatory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery of Bacterial Species Richness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Antibiotic Resistance Genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continued Microbial Disruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of anaerobic bacteria in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bony changes assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tinetti Gait and Balance Test (TGBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-times Sit to Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Speed Measurement Test (GSMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini Mental State Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: changes of diversity of subgingival community
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: changes of prevalence and abundance of OTUs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Participant Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in 12-lead electrocardiogram (ECG) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of Safety laboratory parameters related to liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Safety laboratory parameters related to renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes of Troponin I as a cardiac safety marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AF Detection Rate Within 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urine weight and osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Blood and urine laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of transduced donor-derived cells expressing CMV-specific TCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment toxicity evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Resolution of clinical signs of blepharitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of obstruction reversibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI-PDFF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Loco-regional tumor control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUCt for azacitidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of the treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mortality from liver failure
Endpoint domain: Mortality/survival
Primary endpoint: Successful conversion rate of operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Core Cancer Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: serum VEGF and Ang-2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virtual Environment Liking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety of acute normovolemic hemodilution (ANH)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline ultrasound imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Scale Change (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of Control (Lack of Need for Palliative Intervention of Malignant Pleural Effusions)
Endpoint domain: Adverse events/effects
Primary endpoint: Discomfort scores on a visual analog scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction scores on a visual analog scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in Analgesic Requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Maximum Inspiratory Pressure (MIP) at 7 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in Maximum Expiratory Pressure (MEP) at 7 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood concentration levels of icariin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of EGCs/GCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in mean serum 25-hydroxycholecalciferol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of IV pentamidine
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of physical exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of LDL-cholesterol and HDL-cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to last measurable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to extrapolated to infinity (AUC∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean change in Apnoea-Hypopnoea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recurrent Venous Thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Achievement of Independent Sitting for at Least 30 Seconds
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline PTSD severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score on handwashing checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in aspirin antiplatelet effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of SHR4640 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of main metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate variability (HF/LF ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changed surgical approach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Free From Atrial Fibrillation, Atrial Flutter or Atrial Tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke impairment assessment scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regression of organ damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate and severity of XRT induced xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CMV End Organ Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of CMV Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: North Star Ambulatory Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeration of CTC (circulant tumoral cell)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Assessment of vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriological Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in objective reading performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contraceptive Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in asthma control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerated dose (MTD) of Mogamulizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose limiting toxicity (DLT) of Mogamulizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Psoriasis Area Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically important intracranial bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of progression of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: level of IL-6 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HLA-expression on monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of adverse events in patients with ulcerative colitis receiving EEN
Endpoint domain: Adverse events/effects
Primary endpoint: Change in days spent in inpatient treatment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in graded vitreous haze
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients with arm lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Level of agreement between ROM Plus test and diagnosis of ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Spirometry results after 8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of necrotizing external otitis
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of detection of in-stent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebrospinal fluid flow parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Acute C-peptide Response to Glucose (ACRmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: WHODAS-II Disability Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to first occurrence of renal composite endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Indicators of crisis and suicidality
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients Alive and Without Progression of Disease
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Experiencing Stress Hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in telomere length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive pregnancy test after ICSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Duration of postoperative Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Pre-eclampsia
Endpoint domain: Mortality/survival
Primary endpoint: Freedom From Major Complications Related to the EV ICD System and/or Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Defibrillation Efficacy at Implant of the EV ICD System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time taken to perform a cranial scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Subjects With Dose Limiting Toxicities and Grade 3/4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of First Hospitalisation for Atrial Fibrillation or Flutter (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of First Hospitalisation for Supraventricular Tachycardia (SVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of First Hospitalisation for Ventricular Tachycardia (VT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of First Hospitalisation for Acute Myocardial Infarction (AMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of First Hospitalisation for Serious Acute Coronary Heart Disease (SACHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient-Rated Tennis Elbow Evaluation (PRTEE) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain free grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in safety relevant performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turnaround time for BRCA testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of Minimal Hepatic Encephalopathy (MHE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Renal biomarker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Abnormal Lab Results Resulting in Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Therapeutic Plasma Concentration of Fondaparinux at 21 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients in which long-term (20+ years) contact is maintained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of eligible patients located who were lost to follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Forgotten Knee Scores (FJS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning